Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, announced today its agenda and
distinguished speaker list for a comprehensive Investor Update
Meeting taking place Thursday, December 2nd , from 10:00am ET
– 1:30pm EST.
The event will focus on the company’s US product candidate,
HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic
delivery system), a percutaneous hepatic perfusion (PHP) system. In
the United States HEPZATO is an investigational drug/device
combination product. In Europe, the product is a stand-alone
medical device approved for sale under the trade name CHEMOSAT®
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
A distinguished panel of physicians will discuss their
experience with HEPZATO in the FOCUS trial, commercial experience
with CHEMOSAT and the unmet need in the treatment of liver
metastases. The participating physicians will present on the
following topics:
- Current unmet need and treatment options for liver
metastases
- The longest single institution experience with PHP – The
University Hospital Southampton experience
- PHP quality of life and combination with immuno-oncologic
therapy – The Leiden University experience
- Current unmet needs in ocular melanoma
- Focus Trial – efficacy and safety results
- Future clinical development plans
In addition to the Delcath management team, planned speakers and
panelists will include:
John Bridgewater, MRCP, PhD, FRCPProfessor and Consultant
Medical Oncologist, UCL Cancer Institute, University College
London, London, UK
Mark Burgmans, MD, PhDHead of Interventional Radiology,
Department of Radiology, Leiden University Medical Center, Leiden,
The Netherlands
Aslam Ejaz MD, MPHAssistant Professor of Surgery, The Ohio State
University, Columbus, OH
Francesco Pier Ferrucci, MDDirector, Tumor Biotherapy Unit,
Istituto Europeo di Oncologia, Milan, Italy
Evan S. Glazer, MD, PhD, FACSAssistant Professor of Surgery,
College of Medicine and Principal Investigator, Center for Cancer
Research, The University of Tennessee Health Science Center,
Memphis, TN
Sachin Modi, BSc (Hons), MBBS, FRCR, FRCR (IR)Consultant
Interventional Radiologist, Department of Interventional Radiology,
University Hospital Southampton, Southampton, UK
Siddharth A. Padia, MD HS Clinical Professor, Division of
Interventional Radiology, David Geffen School of Medicine,
University of California, Los Angeles, CA
Sapna Patel, MDAssociate Professor, Department of Melanoma
Medical Oncology, MD Anderson Cancer Center, Houston, TX
Sunil A. Reddy, MDClinical Assistant Professor, Division of
Oncology, Department of Medicine, Stanford University School of
Medicine, Stanford, California
Brian Stedman, BSc, MBBS, FRCS, FRCRConsultant Interventional
Oncologist, Department of Interventional Radiology, University
Hospital Southampton, Southampton, UK
Juan Valle, MDProfessor and Consultant Medical Oncologist, The
Christie NHS Foundation Trust, Manchester, UK
Jonathan Zager, MD, FACS (Global Lead Investigator)Chief
Academic Officer, Director of Regional Therapies, and Senior
Member, Departments of Cutaneous Oncology and Sarcoma, Moffitt
Cancer Center; Chair, Department of Oncological Sciences and
Professor of Surgery, USF, Morsani School of Medicine, Tampa,
FL
Event Details:Event: Delcath Systems
Virtual Investor Update MeetingDate: Thursday, December 2,
2021Time: 10:00am – 1:30 p.m. EST
About Delcath Systems, Inc.Delcath Systems,
Inc. is an interventional oncology company focused on the treatment
of primary and metastatic liver cancers. The company’s proprietary
percutaneous hepatic perfusion (PHP) system is designed to
administer high-dose chemotherapy to the liver while controlling
systemic exposure and associated side effects. In the United
States, the PHP system is being developed under the tradename
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery
system), or HEPZATO, and is considered a combination drug and
device product regulated by the United States Food and Drug
Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024